Our study demonstrated that FREM1 is downregulated in breast cancer tissues compared to normal controls, correlates with poor clinical outcomes and an immunosuppressive tumor microenvironment, and that its overexpression can suppress tumor malignant behaviors. The gene discussed is FREM1; the disease is breast carcinoma.